抗体芯片竞争抑制法检测尿液中吗啡含量

目的建立抗体芯片竞争抑制法检测尿液中吗啡含量的方法。方法将吗啡单克隆抗体固定在用琼脂糖包被的芯片上,与含有吗啡的尿液检材和Cy3荧光标记-吗啡-BSA复合物进行竞争抑制反应,共聚焦扫描仪采集反应图像并进行分析。结果吗啡单克隆抗体及Cy3-吗啡-BSA的最佳浓度是31.25μg/m l、12.50μg/m l,检测线性范围0.01~10ng/m。回收率在91.2%~109.2%之间,尿液检测限为0.02ng/m l。甲基苯丙胺、安非他明与吗啡抗体之间无交叉反应,与可待因有一定的交叉反应。结论抗体芯片竞争抑制法检测尿液中的吗啡含量具有灵敏度高,特异性好、操作简单、高通量等优点,可用于法医毒物检测、戒毒效果监测。     

污水分析中直接进样法与固相萃取法的比较与应用

目的 将本课题组最新研发的测定污水中11种常见毒品及其代谢物的直接进样法与本课题组已发表固相萃取法的定量结果进行比较，以保证直接进样法定量结果的准确性，并对当前常见的污水前处理方法进行比较及应用探究。方法 选取3份已知浓度的添加污水样品及15份未知浓度的实际污水样品，使用两种方法进行样品前处理，并将检测到的相同目标物浓度之间的差异百分比进行计算。结果 两种方法的差异百分比范围为-13.76%～14.00%，这一差异值可被接受。结论 直接进样法可得到良好的定量结果并能满足污水分析的高通量分析要求，同时建议各实验室开发两种污水处理方法，对司法部门加快建设高水平的毒品实验室体系，推进禁毒科技创新具有重要意义。     

运用二重PCR和DNA芯片技术检测ABO基因型

目的以玻片为载体,用寡核苷酸探针杂交技术检测ABO基因型。方法根据ABO基因座外显子6和外显子7的3个SNP点的序列分布特征设计4条寡核苷酸探针,制成分型芯片。将待测样品DNA用末端标记了Cy5的引物进行二重PCR扩增,产物与芯片上的探针进行杂交,根据杂交产生的荧光信号确定样品的ABO基因型。结果利用ABO芯片,可对血斑、毛发等微量检材进行ABO基因型检测。对115名汉族无关个体的调查表明,ABO基因型的分布符合Hardy-Weinberg平衡,等位基因杂合度观察值和期望值分别为0.591、0.616,多态信息含量为0.544,二联体和三联体非父排除率分别为0.188、0.334,个体识别能力为0.777。结论通过DNA芯片检测ABO基因型的技术适用于法医学样本,可满足高通量的检测需求。     

氨基比林血痕预试验处理血痕后样本的DNA定量

目的：探讨氨基比林血痕预试验处理血痕后样本DNA含量的变化及对STR分型检测的影响。方法10名健康无关个体EDTA抗凝血液制成滤纸血痕,氨基比林血痕预试验检测,按试验后血样干燥保存时间分30 min、1 h、3 h、6 h、12 h、24 h共6个实验组,并采用磁珠法、QIAcube DNA纯化法、Chelex-100法三种方法提取样本DNA,应用荧光定量PCR检测样本DNA含量,PCR-STR荧光技术进行STR分型。结果提取方法相同时,氨基比林血痕预试验后血样随干燥保存时间的延长,样本DNA含量呈逐渐降低的趋势。保存时间相同时,不同DNA提取方法间,样本DNA含量差异也有统计学意义。90.56%样本均可获得16个STR基因座明确分型。结论氨基比林血痕预试验对血痕样本DNA有损伤,24 h内多可获有效STR分型。磁珠法提取样本DNA进行STR分型,效果最好。     

DNA芯片技术检测HLA-DRB1和ABO基因型

用DNA芯片技术检测HLA-DRB1-ABO基因型。根据HLA和ABO不同基因亚型的独特序列设计探针,制成分型芯片;待检测样品经PCR反应标记上荧光之后,与探针在芯片上进行杂交,通过对杂交产生的荧光信号值进行分析,确定样品DRB1位点和ABO位点的基因亚型。将这一方法应用于111份样本的HLA-DRB1-ABO基因分型并将部分样品进行基因测序。检测结果证明本实验研制的HLA-DR-ABO基因分型芯片可准确分辨出DRB1位点30个等位基因、ABO位点6种基因型。该方法分辨率高、特异性强、重复性好、操作简便,对比常规的PCR-SSP方法,HLA-DR-ABO基因芯片方法更为直观,并具有集成化优势,可以在一张芯片上同时检测HLA和ABO位点,并实现一张芯片多人份,不仅适用于法医学亲子鉴定和个体识别,亦可应用于移植配型、HLA相关疾病及人类遗传学研究。     

两个体混合样本比例的PCR-STR检测研究

目的探讨PCR-STR检测两个体混合样本比例的灵敏度。方法按不同比例将两个体全血、单个核细胞及纯DNA 3种不同的样本进行混合,应用AB I公司生产的profile p lus商品化试剂盒多重PCR扩增后,用AB I3100基因分析仪进行毛细管电泳,检测基因座及其峰面积,并就混合样本中两单个核细胞样本DNA含量百分比与扩增前混合样本比例的关系进行相关分析。结果当样本混合比例为4%+96%时,可明确区分混合样本中两个体的基因型,且扩增前混合细胞百分率与扩增后两者峰面积比值呈直线相关。结论PCR-STR检测两个体混合样本比例的灵敏度有一定范围,并可进行半定量。     

唾液中乙醇含量检测试剂条的研究

目的根据唾液和血液中乙醇含量相关性的实验结果,建立了一种简便快速、准确可靠的检测唾液中乙醇含量的方法。方法本方法利用酶学原理,将一定量乙醇氧化酶(ALO)和过氧化物酶以及底物四甲基联苯胺(TMB)固定于试剂条上,当样本中含有乙醇时,酶学反应使底物TMB显色,通过比对反应的不同颜色,对样本中乙醇质量浓度进行半定量。结果用本方法检测300个自愿者的唾液,和用GC/MS法对照检测志愿者唾液中的乙醇含量,定量结果基本一致。本产品检测过程仅需2min,其检测的阈值为0.1mg/mL,敏感度为96.5%,特异性为91%,准确性为94.7%。结论采用酶学方法制备的乙醇含量检测试剂条,通过显色反应对唾液中的乙醇含量进行半定量检测,其特点为快速简便、准确可靠,适合现场使用。     

微流控芯片技术在刑事科学中的应用

目的　阐述微流控芯片技术在法庭科学上的应用。方法　研究国内外已报道的微流控芯片快速、灵敏、高通量技术的有关资料。结果　提出在法医DNA检验、毒剂和毒物检测、麻醉剂或毒品检测、爆炸残留物检测等刑事技术上的应用前景。结论　从刑事侦查的角度看出该技术的巨大发展潜力     

毒品特征分析技术在案例中的初步应用

2008年,某部门给我实验室送来一批在2个地区缴获的共50起案件的毒品样本,希望利用毒品特征分析技术对其进行全面的定性、定量分析,通过总结每个样本的组成及含量特征,找出这批毒品样本之间的区别、关联和相似性,以获得相关的毒品情报信息。我实验室运用准确、科学的技术方法将50个案件的毒品分成5组,揭示了每个案件毒品之间内在的区别与联系,为该部门打击毒品犯罪活动提供了重要的战略情报服务。     

MiSeq FGx~(TM)系统进行基因突变亲权鉴定1例

<正>1材料与方法1.1 DNA提取及定量样本来源于本实验室日常案件中经ID-PLUS检测存在STR遗传位点突变的三联体的FTA唾液口腔卡,并使用Qiagen DNA Investigator试剂盒(Qiagen公司)提取样本DNA。样本DNA采用Qubit?3.0荧光定量仪(Life Technologies公司)进行DNA浓度检测,并将浓度稀释到0.2ng/μL[1]。     

Developmental validation of a real-time quantitative PCR assay for automated quantification of human DNA

Our laboratory has developed an automated real-time quantitative PCR assay for detecting human DNA. The assay utilizes an in-house, custom-designed TaqMan-MGB sequence-specific probe (CFS-HumRT) and the ABD 7900HT SDS platform. Developmental validation has followed TWGDAM (1) guidelines and demonstrates that the assay is primate specific, is highly sensitive, yields consistent results, and works with human DNA extracted from a variety of body fluid stains. When operating within the dynamic range of the system using high-quality DNA samples. the technique yields similar quantification results to our current QuantiBlot assay with the added benefit of time saving through automation. Furthermore, the QPCR assay identifies how much amplifiable DNA is in a sample and thus has the potential to predict PCR success in downstream applications such as STR analysis.     

Development of an Antibody Hapten‐Chip System for Detecting the Residues of Multiple Antibiotic Drugs*

Abstract: The abuse of antibiotic drugs during animal production remains a worldwide problem and the subsequent detection of the residues of various drugs present at low concentrations in complex biological matrices poses significant analytical challenges. The present study outlines a practical biochip assay system to identify antibiotic residues in different animal tissue extracts. The system uses a simple but efficient multiresidue sample extraction procedure to isolate the antibiotic residues which were then identified directly using high‐affinity monoclonal antibodies presented in a competitive immunoassay with conjugated antibiotic hapten‐chips. The hapten‐chip can analyze six samples each for eight antibiotics on a single chip within 3 h. The analytical results with both artificial positive standard samples and the incurred samples show that the antibody hapten‐chip system has a comparable accuracy and a similar sensitivity to a standard ultra performance liquid chromatography–mass spectrometry (MS)/MS assay. In conclusion, an effective analytical screening system based on antibody hapten‐chip was developed for detecting multiple antibiotic residues from multiple samples.     

一种改良酸性磷酸酶试验鉴定精斑的方法

本文报道了一种改良的酸性磷酸酶试验方法。用该法鉴定精斑，可克服非特异性反应，排除其它体液和植物汁液的影响。     

LC-MS/MS法快速测定全血中25种精神药物的研究

目的建立人全血中25种精神药物快速测定的LC-MS/MS方法,并应用于分析杭州地区药物影响下驾驶(driving under the inference of drugs,DUID)情况。方法以乙腈沉淀蛋白,离心后取上清液,氮气流下吹干,残渣以初始流动相复溶,离心后取上清分析;采用C18色谱柱(50mm×3.0mm,2.6μm)分离,流动相:0.1%甲酸水(A相),乙腈:甲醇=1:1(B相),梯度洗脱;质谱检测,采用串联质谱电喷雾离子源,正电离扫描,多反应监测(MRM)。结果 25种精神药物在0.05~20ng/m L范围内线性良好,R=0.994 4~0.999 6;定量下限为0.05ng/m L;提取回收率为83.0%~99.7%;方法回收率为80.2%~97.4%;日内精密度(RSD)为1.6%~14%;日间精密度(RSD)为3.1%~14%。以该法测定杭州市公安司法鉴定中心留存的全血样品3140例,25种精神药物至少一种的检出率为3.7%。结论本方法灵敏、快捷、准确,适用于全血中25种精神药物快速检测。     

An enzyme-linked immunosorbent assay (ELISA) for prostate-specific antigen.

A sandwich ELISA for human prostate-specific antigen (PSA) is described. Optimal assay conditions, resulting in a sensitive assay with a low background, are presented. The method uses a hyperimmune antiserum produced in the New Zealand white rabbit, against human semen PSA. The IgG fraction of the antiserum was conjugated with horseradish peroxidase and used in the sandwich ELISA method. The anti-PSA IgG showed no cross reactions with saliva, normal blood, female urine, vaginal fluid, or menstrual blood. On occasions, a blood sample showed a non-specific cross-reaction, which was detected by non-immune rabbit IgG. This reaction could be caused by rheumatoid factors, as indicated by experiments with a series of known IgG and IgM rheumatoid antibodies, although other heterophilic antibodies could not be eliminated. The recovery of PSA added to blood plasma, saliva and vaginal fluid was affected by three factors; (a) protein concentration (dilution) of body fluid; (b) nature of the protein; and (c) amount of PSA added.     

Development of an Alu-based,QSY 7-labeled primer PCR method for quantitation of human DNA in forensic samples

Determining the amount of human DNA extracted from a crime scene sample is an important step in DNA profiling. The forensic community relies almost entirely upon a technique (slot blot) to quantitate human DNA that is imprecise, time consuming, and labor intensive. This paper describes the development of a new technique based on PCR amplification of a repetitive Alu sequence. Specific primers were used to amplify a 124-bp fragment of Alu sequence; amplification was detected by SYBR Green I staining in a fluorescent plate reader. To reduce background in the plate reader assay, QSY-7 labeled primers were utilized. The assay was tested on animal DNAs, human blood spots, mock crime samples, and degraded DNA in comparison with the slot blot technique. The QSY Alu assay has a dynamic range of 10 ng to 10 pg, and is sensitive, specific, fast, quantitative, and comparable in cost to the slot blot assay.     

A novel multiplex assay system based on 10 methylation markers for forensic identification of body fluids

Identifying the source of body fluids found at a crime scene is an essential forensic step. Some methods based on DNA methylation played significant role in body fluids identification. Since DNA methylation is related to multiple factors, such as race, age, and diseases, it is necessary to know the methylation profile of a given population. In this study, we tested 19 body fluid-specific methylation markers in a Chinese Han population. A novel multiplex assay system based on the selected markers with smaller variation in methylation and stronger tissue-specific methylation were developed for the identification of body fluids. The multiplex assay were tested in 265 body fluid samples. A random forest model was established to predict the tissue source based on the methylation data of the 10 markers. The multiplex assay was evaluated by testing the sensitivity, the mixtures, and old samples. For the result, the novel multiplex assay based on 10 selected methylation markers presented good methylation profiles in all tested samples. The random forest model worked extremely well in predicting the source of body fluids, with an accuracy of 100% and 97.5% in training data and test data, respectively. The multiplex assay could accurately predict the tissue source from 0.5 ng genomic DNA, six-months-old samples and distinguish the minor component from a mixture of two components. Our results indicated that the methylation multiplex assay and the random forest model could provide a convenient tool for forensic practitioners in body fluid identification.     

The toxicological challenges in the European research project DRUID

Within the epidemiological studies of the integrated European research project DRUID (Driving Under the Influence of Drugs, alcohol and medicines), 13 laboratories from across Europe will analyse whole blood, oral fluid (OF) or urine from the general driving population and injured drivers. To ensure the comparability of toxicological results from the different studies, the collection of samples, analytical methods, target analytes and analytical cut-offs have been standardized for all laboratories involved.Target analytes were selected based on suspected impairing effects and prevalence. Twenty-three drugs are included in the ‘core list’ for which analysis is mandatory: ethanol, amphetamine, MDMA, MDA, MDEA, methamphetamine, cocaine, benzoylecgonine, THC, THC-COOH, 6-acetylmorphine, diazepam, flunitrazepam, alprazolam, clonazepam, oxazepam, nordiazepam, zolpidem, zopiclone, lorazepam, morphine, codeine and methadone. Additionally, 28 other drugs will be analysed in 1–12 countries.All whole blood samples are collected in glass Vacutainer-type tubes containing sodium fluoride and potassium oxalate. Based on a comparative study of 10 collection devices, it was decided to collect oral fluid using the Statsure™ device. Since only a small sample volume is available (5–10 mL blood and 1 mL oral fluid), all laboratories have to develop methods for simultaneous detection of the target analytes. All laboratories agreed to use either LC–MS–MS or GC–MS in SIM-mode. Proficiency testing for both blood and oral fluid are organized.Analytical cut-offs were established for the core list based on those used in ROSITA-2, SAMHSA cut-off values for oral fluid and recommendations from an expert meeting in Talloires.Because of practical and legal considerations, different sample types are used: whole blood, serum/plasma and oral fluid. Literature on correlation between analyte concentrations in these body fluids is limited, which makes several comparisons of study results difficult: (1) comparison of epidemiological (blood, oral fluid and urine) and experimental studies (serum and plasma) performed in DRUID and (2) comparisons within the epidemiological studies themselves (most countries: oral fluid in road-side survey, blood in hospital studies).A combination of literature findings, new findings from DRUID and semi-quantitative results will likely have to be used to solve these problems.     

Validation of the Cozart Amphetamine Microplate EIA for the analysis of amphetamines in oral fluid

The purpose of this study was to determine the performance characteristics of the Cozart Amphetamine Microplate EIA for detecting amphetamine in oral fluid. Oral fluid samples were collected using the Cozart RapiScan Collection System from 135 volunteer donors from drug treatment clinics. A further 35 oral fluid samples were collected from volunteer donors who were not drug users. The samples were analyzed in the laboratory using the Cozart Amphetamine Microplate EIA and confirmed using gas chromatography-mass spectrometry (GC-MS). The samples were stored frozen until analysis by GC-MS. The intra-assay precision for the Cozart Amphetamine Microplate EIA for amphetamine in oral fluid over forty assays was 2.74-7.1% CV (within assay) and 3.4-7.0% CV (within day). A total of 78 samples were positive for various amphetamines and related designer drugs. The Cozart Amphetamine Microplate EIA, using a cutoff of 45 ng/ml amphetamine equivalents in neat oral fluid, had a sensitivity of 91.7+/-3.3% and a specificity of 95.9+/-1.9% versus GC-MS using a cutoff of 30 ng/ml. A series of potential adulterants of oral fluid were evaluated and shown not to alter the outcome of the test result.     

人类岩藻糖基转移酶5特异性分布及其在精细胞的表达与定位

目的研究人类岩藻糖基转移酶5(fucosyltransferase 5,FUT5)的特异性分布及在精细胞的表达与定位。方法收集健康志愿者的精液(分离精细胞并提取精细胞膜蛋白)、阴道拭子、唾液及静脉血,应用免疫印迹方法检测FUT5在人类精细胞膜、精浆、阴道液、唾液及血清中的表达量,采用免疫荧光技术检测FUT5在精细胞中的表达与定位。结果免疫印迹方法结果显示FUT5在精细胞膜及血清中有较高表达,但在精浆、阴道液及唾液中未被检测到。免疫荧光实验结果显示FUT5主要存在于精细胞头部。表明人类精细胞膜存在一定表达量的特异性FUT5,可采用抗原-抗体反应分离精液和阴道液混合斑中的精细胞。结论人类FUT5表现出分布特异性,可应用到法医学性犯罪案件中混合斑的鉴定。